非ST段抬高型院外心脏骤停后快速转运至心脏骤停中心(ARREST):英国前瞻性、多中心、平行、随机临床试验
ARREST为英国前瞻性、多中心、平行、开放标签、优效性随机试验,纳入院外心脏骤停复苏后无ST段抬高的成人患者,随机1:1分为快速转运至7家心脏骤停中心之一的心脏导管室(431例)或标准治疗转运至伦敦32家医院中距现场最近的急诊科(431例)。主要终点30天全因死亡率在心脏骤停中心组为258/411(63%),标准治疗组为258/412(63%),生存未校正风险比1.00(95%CI 0.90-1.11;p=0.96)。严重不良事件分别为8/414(2%)和3/413(1%),均被认为与试验干预无关。作者结论:在无ST段抬高的成人中,院外心脏骤停复苏后转运至心脏骤停中心未减少死亡。
要点
- 随机1:1比较快速转运至心脏骤停中心(7家)vs标准治疗转运至最近急诊科(32家),纳入无ST段抬高的成人院外心脏骤停复苏后患者。
- 30天死亡率心脏骤停中心组258/411(63%)vs标准治疗组258/412(63%),生存未校正风险比1.00(95%CI 0.90-1.11;p=0.96)。
- 严重不良事件心脏骤停中心组8/414(2%)vs标准治疗组3/413(1%),均认为与试验干预无关。
- 作者结论:无ST段抬高的成人院外心脏骤停复苏后,转运至心脏骤停中心未减少死亡。
适用人群与场景
- 年龄≥18岁、院外心脏骤停复苏后恢复自主循环且无ST段抬高的患者。
- 在心脏骤停现场由伦敦救护服务人员随机分组;干预组转运至7家心脏骤停中心之一的心脏导管室,对照组转运至伦敦32家医院中距现场最近的急诊科。
研究设计与关键结果
- ARREST为前瞻性、平行、多中心、开放标签、优效性随机试验,2018年1月15日至2022年12月1日共纳入862例,心脏骤停中心组431例(50%)、标准治疗组431例(50%)。
- 心脏骤停中心组20例、标准治疗组19例因缺乏知情同意或死亡状态未知退出,主要分析纳入心脏骤停中心组411例、标准治疗组412例。
- 822例有数据者中男性560例(68%)、女性262例(32%)。
- 主要终点30天死亡率:心脏骤停中心组258/411(63%)vs标准治疗组258/412(63%),生存未校正风险比1.00(95%CI 0.90-1.11;p=0.96)。
- 严重不良事件:心脏骤停中心组8/414(2%)vs标准治疗组3/413(1%),均认为与试验干预无关。
证据类型、等级与局限
- 证据类型:前瞻性、多中心、平行、开放标签、优效性随机临床试验(ARREST),于国际标准随机对照试验注册库前瞻性注册(96585404)。
- 局限:救护车实施干预人员及报告院内治疗结局人员无法设盲。
对床旁实践的改变
- 作者结论:在无ST段抬高的成人中,院外心脏骤停复苏后转运至心脏骤停中心未减少死亡。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The International Liaison Committee on Resuscitation has called for a randomised trial of delivery to a cardiac arrest centre. We aimed to assess whether expedited delivery to a cardiac arrest centre compared with current standard of care following resuscitated cardiac arrest reduces deaths.
METHODS: ARREST is a prospective, parallel, multicentre, open-label, randomised superiority trial. Patients (aged ≥18 years) with return of spontaneous circulation following out-of-hospital cardiac arrest without ST elevation were randomly assigned (1:1) at the scene of their cardiac arrest by London Ambulance Service staff using a secure online randomisation system to expedited delivery to the cardiac catheter laboratory at one of seven cardiac arrest centres or standard of care with delivery to the geographically closest emergency department at one of 32 hospitals in London, UK. Masking of the ambulance staff who delivered the interventions and those reporting treatment outcomes in hospital was not possible. The primary outcome was all-cause mortality at 30 days, analysed in the intention-to-treat (ITT) population excluding those with unknown mortality status. Safety outcomes were analysed in the ITT population. The trial was prospectively registered with the International Standard Randomised Controlled Trials Registry, 96585404.
FINDINGS: Between Jan 15, 2018, and Dec 1, 2022, 862 patients were enrolled, of whom 431 (50%) were randomly assigned to a cardiac arrest centre and 431 (50%) to standard care. 20 participants withdrew from the cardiac arrest centre group and 19 from the standard care group, due to lack of consent or unknown mortality status, leaving 411 participants in the cardiac arrest centre group and 412 in the standard care group for the primary analysis. Of 822 participants for whom data were available, 560 (68%) were male and 262 (32%) were female. The primary endpoint of 30-day mortality occurred in 258 (63%) of 411 participants in the cardiac arrest centre group and in 258 (63%) of 412 in the standard care group (unadjusted risk ratio for survival 1·00, 95% CI 0·90-1·11; p=0·96). Eight (2%) of 414 patients in the cardiac arrest centre group and three (1%) of 413 in the standard care group had serious adverse events, none of which were deemed related to the trial intervention.
INTERPRETATION: In adult patients without ST elevation, transfer to a cardiac arrest centre following resuscitated cardiac arrest in the community did not reduce deaths.
FUNDING: British Heart Foundation.
参考来源
- Patterson T, Perkins GD, Perkins A, et al. Expedited transfer to a cardiac arrest centre for non-ST-elevation out-of-hospital cardiac arrest (ARREST): a UK prospective, multicentre, parallel, randomised clinical trial. Lancet. 2023. PMID: 37647928. doi:10.1016/S0140-6736(23)01351-X
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。